The treatment landscape for elderly patients with acute myeloid leukemia (AML), which has a 5-year relative survival rate of less than 10%, is changing with the introduction of a new drug that addresses the unmet needs and improves survival rate.

AML is one of the most common types of leukemia in adults with a high unmet need in patients and HCPs alike. As one of the more aggressive types of leukemia in adults, around 140,000 new cases occur globally every year, of which around 100,000 cases end in deaths.

With the same treatment being used in AML for over 40 years, not much improvement has been made in the overall survival (OS) until recently. The 5-year survival rate was at a mere 29%